Adlai Nortye(NASDAQ) ANL

Market Cap$446.04M

Since IPO (2023)-13%

5 YearN/A

1 Year+796%

1 Month+37%

$12.87

-1.00%

-0.13Today

After hours$12.98+$0.11 (+0.86%)

Adlai Nortye last closing stock price
Metric	Price	Date
Last close	USD 12.99	2026-08-03

Adlai Nortye stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+7.71%	USD 12.06	2026-07-27
1 month	+36.88%	USD 9.49	2026-07-02
3 month	-12.99%	USD 14.93	2026-05-05
Year to date	+814.79%	USD 1.42	2025-12-31
1 year	+795.86%	USD 1.45	2025-08-01
Since inception	-13.33%	USD 15.00	2023-09-29

Adlai Nortye Financials at a Glance

Market Cap

$446.04M

Revenue (TTM)

$6.49M

Net Income (TTM)

-$44.81M

EPS (TTM)

-$1.01

P/E Ratio

-12.91

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$12.87

Volume

216,584.377

Open

$12.99

Price

$12.87

Volume

216,584.377

Open

$12.99

Previous Close

$12.99

Daily Range

$12.70 - $13.41

52-Week Range

$0.88 - $17.25

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$12.87

Volume

216,584.377

Open

$12.99

Previous Close

$12.99

Daily Range

$12.70 - $13.41

52-Week Range

$0.88 - $17.25

Estimated Earnings Date

Aug 6, 2026

ANL News

No articles available.

ANL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adlai Nortye

Adlai Nortye Ltd. is a biopharmaceutical company that focuses on developing innovative oncology therapies. Through strategic research, partnerships, and cutting-edge technology, the company aims to provide transformative cancer treatments worldwide.

Products and Services

Development of oncology therapies using immunotherapy techniques

Utilization of kinase inhibitors for cancer treatment

Supportive collaborations with global research institutions

What Makes Adlai Nortye Ltd. Special

Adlai Nortye Ltd. stands out due to its cutting-edge immunotherapy and kinase inhibitor strategies that target cancer treatment. The company builds robust partnerships to enhance its research and development capabilities, which accelerates progress and innovation in its therapeutic advancements.

Five Things You Need to Know

Adlai Nortye is focused on the precision medicine landscape in oncology.

The company leverages immunotherapy to treat cancer effectively.

It maintains strategic alliances with leading global research institutions.

Adlai Nortye's leadership has deep industry expertise in biopharma.

The company prioritizes the expansion and diversification of its product pipeline through in-licensing opportunities.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

109

CEO

Yang Lu, EMBA

Website

www.adlainortye.com

Headquarters

Grand Cayman, KY1-1104, US

ANL Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-330.48%

Net Income Margin

-343.86%

Return on Equity

591.30%

Return on Capital

-197.73%

Return on Assets

-49.93%

Earnings Yield

-7.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$446.04M

Shares Outstanding

34.34M

Volume

216.58K

Avg. Volume

181.68K

Financials (TTM)

Gross Profit

$6.49M

Operating Income

-$45.77M

EBITDA

-$44.79M

Operating Cash Flow

-$46.70M

Capital Expenditure

-$309.00K

Free Cash Flow

-$47.01M

Cash & ST Invst.

$23.79M

Total Debt

$26.38M

Adlai Nortye Performance Analysis

Adlai Nortye annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 5,013,224	N/A

Adlai Nortye sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-12-31	N/A
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A

Adlai Nortye annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.80	3.5%
2023	2023-12-31	USD -7.55	320.1%
2024	2024-12-31	USD -1.63	-78.5%
2025	2025-12-31	USD -1.11	-31.5%

Adlai Nortye sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-12-31	N/A
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$2.50M

+0.0%

Gross Profit

$2.50M

+0.0%

Gross Margin

100.00%

N/A

Market Cap

$446.04M

N/A

Market Cap/Employee

$4.09M

N/A

Employees

109

N/A

Net Income

-$8.60M

+35.0%

EBITDA

-$8.07M

+53.7%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

$23.79M

-75.7%

Total Debt

$26.38M

-32.2%

Accounts Receivable

$1.39M

-39.4%

Inventory

$0.00

N/A

Long Term Debt

$1.13M

N/A

Short Term Debt

$25.25M

-35.1%

Return on Assets

-49.93%

N/A

Return on Invested Capital

2.30%

N/A

Free Cash Flow

-$9.26M

+51.8%

Operating Cash Flow

-$9.17M

+52.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ADAPAdaptimmune Therapeutics plc

ADAPAdaptimmune Therapeutics plc$0.05-3.00%

APLMApollomics, Inc.

APLMApollomics, Inc.$17.00-1.45%

LPCNLipocine Inc.

LPCNLipocine Inc.$2.11-0.47%

BLRXBioLineRx Ltd.

BLRXBioLineRx Ltd.$2.66-5.78%

OSRHOSR Holdings, Inc.

OSRHOSR Holdings, Inc.$0.45-0.42%

ICUSeaStar Medical Holding Corporation

ICUSeaStar Medical Holding Corporation$3.20+2.08%

AIMDAinos, Inc.

AIMDAinos, Inc.$1.45+9.02%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$41.43-0.05%

NVDANvidia

NVDANvidia$206.64+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.81+0.07%

INTCIntel

INTCIntel$91.00+0.01%

SNAPSnap

SNAPSnap$5.04+0.07%

AMZNAmazon

AMZNAmazon$284.02+0.05%

SOFISoFi Technologies

SOFISoFi Technologies$18.03+0.11%

Questions About ANL

What is the current price of Adlai Nortye?

Adlai Nortye is trading at $12.99 per share.

What is the 52-week range for Adlai Nortye?

Over the past 52 weeks, Adlai Nortye has traded between $0.88 and $17.25.

How much debt does Adlai Nortye have?

As of the most recent reporting period, Adlai Nortye reported total debt of $26.38M.

How much cash does Adlai Nortye have on hand?

Adlai Nortye reported $23.79M in cash and cash equivalents in its most recent financial results.

What is Adlai Nortye’s dividend yield?

Adlai Nortye does not currently have a dividend yield.

Adlai Nortye(NASDAQ) ANL

Adlai Nortye Financials at a Glance

ANL News

ANL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Adlai Nortye

Products and Services

What Makes Adlai Nortye Ltd. Special

Five Things You Need to Know

ANL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Adlai Nortye Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ANL

What is the current price of Adlai Nortye?

What is the 52-week range for Adlai Nortye?

How much debt does Adlai Nortye have?

How much cash does Adlai Nortye have on hand?

What is Adlai Nortye’s dividend yield?

Premium Investing Services